Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has provided an updated notification to the ASX on its on‑market share buy-back, confirming that it is repurchasing ordinary fully paid shares under an existing buy-back program first notified in October 2025. As of 19 December 2025, the company reports a cumulative 3,370,516 shares bought back prior to the previous trading day and a further 200,000 shares repurchased on the previous day, indicating continued execution of its capital management strategy and a likely focus on enhancing shareholder value and optimising its balance sheet through reducing the number of shares on issue.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed healthcare company operating in the pathology and diagnostic services sector, providing laboratory testing and related services through its network to healthcare providers and patients across Australia.
Average Trading Volume: 796,120
Technical Sentiment Signal: Buy
Current Market Cap: A$537.3M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.